Preservation of β-Cell Function: The Key to Diabetes Prevention
The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Abstract
CONTEXT: The Centers for Disease Control and Prevention estimates that there are approximately 79,000,000 individuals in the United States with prediabetes [impaired glucose tolerance (IGT) and/or impaired fasting glucose] and that approximately 40-50% will progress to type 2 diabetes mellitus (T2DM) during their lifetime. Therefore, treatment of high-risk IGT individuals to prevent T2DM has important medical, economic, social, and human implications. Individuals in the upper tertile of IGT are maximally/near-maximally insulin resistant, have lost 70-80% of their β-cell function, and have approximately a 10% incidence of diabetic retinopathy. Therefore, preservation of the remaining 20-30% of β-cell function is critical to prevent future development of T2DM. EVIDENCE ACQUISITION: We searched MEDLINE from 2000 to the present to identify placebo-controlled trials in which individuals with IGT received pharmacological therapy to prevent progression to diabetes. EVIDENCE SYNTHESIS: Lifestyle modification reduces IGT conversion to T2DM, but it is difficult to implement and maintain. Moreover, 40-50% of IGT subjects progress to T2DM despite weight loss. In contrast, pharmacological intervention with medications that reverse known pathophysiological abnormalities (β-cell dysfunction and insulin resistance) uniformly prevents IGT progression to T2DM. Thiazolidinediones reduce IGT conversion to diabetes by approximately 50-70%. Metformin in the U.S. Diabetes Prevention Program reduced the development of T2DM by 31% and has been recommended by the American Diabetes Association. Because glucagon-like peptide-1 analogs augment insulin secretion, preserve β-cell function, and promote weight loss, they may be efficacious in preventing IGT progression to T2DM. CONCLUSION: Pharmacological intervention with a variety of agents (thiazolidinediones, metformin, acarbose, glucagon-like peptide-1 analogs) consistently reduces the rate of conversion of IGT to T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fasting plasma glucose values are determined by endogenous glucose production (EGP) that is mostly dependent on the liver.”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The product of EGP and fasting insulin is used as a marker of hepatic insulin resistance and it shows a relatively strong relationship with fasting glycaemia.38,39,45”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“Both IFG and IGT subjects present with insulin resistance, however the site of insulin resistance is different: High hepatic insulin resistance is a typical finding in IFG with almost normal values in skeletal muscle.38,39,45 In IGT, the main site of insulin resistance is the muscle with only modest changes in liver insulin sensitivity.37,38”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The primary aim of lifestyle interventions is to prevent or delay the development of type 2 diabetes and its complications13,45 by targeting obesity and physical inactivity, the two most important modifiable risk factors of diabetes development.3,25”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The glitazones, such as troglitazone, rosiglitazone and pioglitazone, act through the PPAR-γ receptor by increasing hepatic and peripheral insulin sensitivity and preserving insulin secretion.45,95”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535
Self-citationDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Self-citationBuchanan, T. A., & Xiang, A. H. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524531 · Cited by 2,123
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationImpaired Fasting Glucose and Impaired Glucose Tolerance
Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc07-9920 · Cited by 1,396
Self-citationGlucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Self-citationBuchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Eriksson, K. F., & Lindg�rde, F. (1991) · Diabetologia · doi:10.1007/bf00400196 · Cited by 1,092
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., & Olefsky, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 926
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Self-citationAbdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Self-citationHerman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
(1997) · Diabetes reviews · Cited by 671
Self-citationBays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Self-citationThe Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 660
Edelstein, S. L., Knowler, W. C., Bain, R. P., Andres, R., Barrett-Connor, E. L., Dowse, G. K., Haffher, S. M., Pettitt, D. J., Sorkin, J. D., Muller, D. C., et al. (1997) · Diabetes · doi:10.2337/diab.46.4.701 · Cited by 641
Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 629
Polonsky, K. S., Sturis, J., & Bell, G. I. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341207 · Cited by 595
Impaired Glucose Tolerance as a Disorder of Insulin Action
Lillioja, S., Mott, D. M., Howard, B. V., Bennett, P. H., Yki-Järvinen, H., Freymond, D., Nyomba, B. L., Zurlo, F., Swinburn, B., & Bogardus, C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181901 · Cited by 578
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Self-citationT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
DeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515
Self-citationInnate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism
Slack, E., Hapfelmeier, S., Stecher, B., Velykoredko, Y., Stoel, M., Lawson, M. A. E., Geuking, M. B., Beutler, B., Tedder, T. F., Hardt, W.-D., et al. (2009) · Science · doi:10.1126/science.1172747 · Cited by 503
Abdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Self-citationGlucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program
The Diabetes Prevention Program Research Group* (2005) · Diabetes · doi:10.2337/diabetes.54.4.1150 · Cited by 474
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
The Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.8.2404 · Cited by 446
Wing, R. R., Goldstein, M. G., Acton, K. J., Birch, L. L., Jakicic, J. M., Sallis, J. F., Smith-West, D., Jeffery, R. W., & Surwit, R. S. (2001) · Diabetes Care · doi:10.2337/diacare.24.1.117 · Cited by 446
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
The natural history of impaired glucose tolerance in the Pima Indians
Saad, M. F., Knowler, W. C., Pettitt, D. J., Nelson, R. G., Mott, D. M., & Bennett, P. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812083192302 · Cited by 413
Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
DEFRONZO, R. A., BARZILAI, N., & SIMONSON, D. C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1294 · Cited by 408
Self-citationMiyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407
Self-citationXiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Kawakubo, M., & Buchanan, T. A. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1066 · Cited by 402
Ziegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., Mielck, A., & for the KORA Study Group (2008) · Diabetes Care · doi:10.2337/dc07-1796 · Cited by 397
Haffner, S. M., Stern, M. P., Mitchell, B. D., Hazuda, H. P., & Patterson, J. K. (1990) · Diabetes · doi:10.2337/diab.39.3.283 · Cited by 397
Haffner, S. M., Stern, M. P., Mitchell, B. D., Hazuda, H. P., & Patterson, J. K. (1990) · Diabetes · doi:10.2337/diabetes.39.3.283 · Cited by 397
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Identification of Individuals With Insulin Resistance Using Routine Clinical Measurements
Stern, S. E., Williams, K., Ferrannini, E., DeFronzo, R. A., Bogardus, C., & Stern, M. P. (2005) · Diabetes · doi:10.2337/diabetes.54.2.333 · Cited by 384
Self-citationDiabetes Prevention Program Research Group (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02043.x · Cited by 363
Weyer, C., Tataranni, P. A., Bogardus, C., & Pratley, R. E. (2001) · Diabetes Care · doi:10.2337/diacare.24.1.89 · Cited by 357
What is the best predictor of future type 2 diabetes
Abdul-Ghani, M. A., Williams, K., DeFronzo, R. A., & Stern, M. (2007) · Diabetes Care · doi:10.2337/dc06-1331 · Cited by 355
Self-citationReduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006
Cheung, B. M. Y., Ong, K. L., Cherny, S. S., Sham, P.-C., Tso, A. W. K., & Lam, K. S. L. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.047 · Cited by 348
Henry, R. R., Wallace, P., & Olefsky, J. M. (1986) · Diabetes · doi:10.2337/diab.35.9.990 · Cited by 325
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Garg, R., Chen, W., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 322
Quality of Diabetes Care in U.S. Academic Medical Centers
Grant, R. W., Buse, J. B., Meigs, J. B., & for the University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team (2005) · Diabetes Care · doi:10.2337/diacare.28.2.337 · Cited by 311
Metformin: A review of its metabolic effects
Cusi, K. J., & DeFronzo, R. A. (1998) · Diabetes reviews · Cited by 310
Self-citationKawamori, R., Tajima, N., Iwamoto, Y., Kashiwagi, A., Shimamoto, K., & Kaku, K. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60222-1 · Cited by 303
Abdul-Ghani, M. A., Abdul-Ghani, T., Ali, N., & DeFronzo, R. A. (2008) · Diabetes Care · doi:10.2337/dc08-0225 · Cited by 302
Self-citationLifestyle Intervention for Prevention of Type 2 Diabetes in Primary Health Care
Saaristo, T., Moilanen, L., Korpi-Hyövälti, E., Vanhala, M., Saltevo, J., Niskanen, L., Jokelainen, J., Peltonen, M., Oksa, H., Tuomilehto, J., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0410 · Cited by 302
The evolution of β‐cell dysfunction and insulin resistance in type 2 diabetes
Bergman, R. N., Finegood, D. T., & Kahn, S. E. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.5.x · Cited by 301
Gillies, C. L., Lambert, P. C., Abrams, K. R., Sutton, A. J., Cooper, N. J., Hsu, R. T., Davies, M. J., & Khunti, K. (2008) · BMJ · doi:10.1136/bmj.39545.585289.25 · Cited by 290
Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62162-0 · Cited by 287
The ten-year follow-up of the Bedford Survey (1962?1972): Glucose tolerance and diabetes
Keen, H., Jarrett, R. J., & McCartney, P. (1982) · Diabetologia · doi:10.1007/bf00254832 · Cited by 283
Physical training and insulin sensitivity
Koivisto, V. A., Yki‐Järvinen, H., & DeFronzo, R. A. (1986) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610010407 · Cited by 258
Self-citationFasting Versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes
Abdul-Ghani, M. A., Lyssenko, V., Tuomi, T., DeFronzo, R. A., & Groop, L. (2009) · Diabetes Care · doi:10.2337/dc08-1264 · Cited by 247
Self-citationDose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes
Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.517 · Cited by 236
Self-citationHiga, M., Zhou, Y.-T., Ravazzola, M., Baetens, D., Orci, L., & Unger, R. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11513 · Cited by 235
A two-step model for development of non-insulin-dependent diabetes
Saad, M. F., Knowler, W. C., Pettitt, D. J., Nelson, R. G., Charles, M. A., & Bennett, P. H. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80165-i · Cited by 234
Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Lee, E. T., Howard, B. V., Savage, P. J., Cowan, L. D., Fabsitz, R. R., Oopik, A. J., Yeh, J., Go, O., Robbins, D. C., & Welty, T. K. (1995) · Diabetes Care · doi:10.2337/diacare.18.5.599 · Cited by 212
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
Self-citationDungan, J. S. (2011) · Yearbook of Obstetrics, Gynecology and Women's Health · doi:10.1016/j.yobg.2011.05.175 · Cited by 173
Development of a Type 2 Diabetes Risk Model From a Panel of Serum Biomarkers From the Inter99 Cohort
Kolberg, J. A., Jørgensen, T., Gerwien, R. W., Hamren, S., McKenna, M. P., Moler, E., Rowe, M. W., Urdea, M. S., Xu, X. M., Hansen, T., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1935 · Cited by 164
An Update on The Diabetes Prevention Program
Ratner, R. E. (2006) · Endocrine Practice · doi:10.4158/ep.12.s1.20 · Cited by 162
Moriya, R., Shirakura, T., Ito, J., Mashiko, S., & Seo, T. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00412.2009 · Cited by 156
Kriska, A. M., LaPorte, R. E., Pettitt, D. J., Charles, M.-A. A., Nelson, R. G., Kuller, L. H., Bennett, P. H., & Knowler, W. C. (1993) · Diabetologia · doi:10.1007/bf00400363 · Cited by 154
Buchanan, T. A., Xiang, A., Kjos, S. L., Lee, W. P., Trigo, E., Nader, I., Bergner, E. A., Palmer, J. P., & Peters, R. K. (1998) · Diabetes · doi:10.2337/diab.47.8.1302 · Cited by 141
Cowie, C. C., Harris, M. I., Silverman, R. E., Johnson, E. W., & Rust, K. F. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116732 · Cited by 139
Rosiglitazone Improves Downstream Insulin Receptor Signaling in Type 2 Diabetic Patients
Miyazaki, Y., He, H., Mandarino, L. J., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.8.1943 · Cited by 135
Self-citationLoss of beta cell function as fasting glucose increases in the non-diabetic range
Godsland, I. F., Jeffs, J. A. R., & Johnston, D. G. (2004) · Diabetologia · doi:10.1007/s00125-004-1454-z · Cited by 131
Metabolic and molecular basis of insulin resistance
Bajaj, M., & DeFronzo, R. A. (2003) · Journal of Nuclear Cardiology · doi:10.1016/s1071-3581(03)00520-8 · Cited by 131
Self-citationAbdul-Ghani, M. A., Williams, K., DeFronzo, R., & Stern, M. (2006) · Diabetes Care · doi:10.2337/dc05-1711 · Cited by 128
Self-citationPratipanawatr, W., Pratipanawatr, T., Cusi, K., Berria, R., Adams, J. M., Jenkinson, C. P., Maezono, K., DeFronzo, R. A., & Mandarino, L. J. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2572 · Cited by 118
Self-citationBuchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Berkowitz, K., Marroquin, A., Goico, J., Ochoa, C., & Azen, S. P. (2000) · Diabetes · doi:10.2337/diabetes.49.5.782 · Cited by 111
Rask, E., Olsson, T., Söderberg, S., Holst, J. J., Tura, A., Pacini, G., & Åhrén, B. (2004) · Metabolism · doi:10.1016/j.metabol.2003.11.011 · Cited by 99
Effect of Various Diuretic Treatments on Rosiglitazone-Induced Fluid Retention
Karalliedde, J., Buckingham, R., Starkie, M., Lorand, D., Stewart, M., & Viberti, G. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006060606 · Cited by 98
Jarrett, R. J., Keen, H., & McCartney, P. (1984) · Diabetic Medicine · doi:10.1111/j.1464-5491.1984.tb01973.x · Cited by 96
Berkowitz, K., Peters, R., Kjos, S. L., Goico, J., Marroquin, A., Dunn, M. E., Xiang, A., Azen, S., & Buchanan, T. A. (1996) · Diabetes · doi:10.2337/diab.45.11.1572 · Cited by 95
The Diabetes Prevention Program Research Group, Venditti, E. M., Bray, G. A., Carrion-Petersen, M. L., Delahanty, L. M., Edelstein, S. L., Hamman, R. F., Hoskin, M. A., Knowler, W. C., & Ma., Y. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.134 · Cited by 93
Abdul-Ghani, M. A., Matsuda, M., Jani, R., Jenkinson, C. P., Coletta, D. K., Kaku, K., & DeFronzo, R. A. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00674.2007 · Cited by 91
Self-citationImpaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism
Jallut, D., Golay, A., Munger, R., Frascarolo, P., Schutz, Y., Jéquier, E., & Felber, J. P. (1990) · Metabolism · doi:10.1016/0026-0495(90)90168-c · Cited by 83
Byrne, M. M., Gliem, K., Wank, U., Arnold, R., Katschinski, M., Polonsky, K. S., & Goke, B. (1998) · Diabetes · doi:10.2337/diab.47.8.1259 · Cited by 55
Ahren, B., Larsson, H., & Holst, J. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370127 · Cited by 55
Diamond, M. P., Thornton, K. L., Connolly-Diamond, M., Sherwin, R. S., & DeFronzo, R. A. (1995) · Journal of the Society for Gynecologic Investigation · doi:10.1016/1071-5576(95)00023-8 · Cited by 54
Self-citationSasaki, A., Suzuki, T., & Horiuchi, N. (1982) · Diabetologia · doi:10.1007/bf00283743 · Cited by 54
Ferrannini, E., Gastaldelli, A., Matsuda, M., Miyazaki, Y., Pettiti, M., Glass, L., & DeFronzo, R. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021864 · Cited by 46
Self-citationArthur, R. J. (1988) · PubMed · Cited by 41
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus
Triplitt, C., & DeFronzo, R. A. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.3.329 · Cited by 25
Self-citationBenefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Gallwitz, B. (2010) · Drug Safety · doi:10.2165/11319130-000000000-00000 · Cited by 24
Miyazaki, Y., De Filippis, E., Bajaj, M., Wajcberg, E., Glass, L., Triplitt, C., Cersosimo, E., Mandarino, L. J., & Defronzo, R. A. (2005) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514050050010601 · Cited by 18
Self-citationBunck, M. C. M., Corner, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M., Smith, U., Yki‐Järvinen, H., & Diamant, M. (2010) · Pure Amsterdam UMC · Cited by 2
UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years
UK Prospective Diabetes Study (UKPDS) Group, Matthews, D. R., Cull, C. A., Stratton, I. M., Holman, R. R., & Turner, R. C. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199804)15:4
Cited by
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationMetformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
Mitochondrial and metabolic dysfunction in ageing and age-related diseases
Amorim, J. A., Coppotelli, G., Rolo, A. P., Palmeira, C. M., Ross, J. M., & Sinclair, D. A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00626-7 · Cited by 990
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
Divakaruni, A. S., Wiley, S. E., Rogers, G. W., Andreyev, A. Y., Petrosyan, S., Loviscach, M., Wall, E. A., Yadava, N., Heuck, A. P., Ferrick, D. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303360110 · Cited by 308
“Thiazolidinediones (TZDs) are the most effective agents for preventing the progression from hyperglycemia to type 2 diabetes (6), and the increasingly appreciated link between dysregulated glucose metabolism and human disease has triggered the repurposing of pioglitazone to treat neurodegenerative conditions and certa…”
Background
Metadata
- Authors
- DeFronzo, R. A., & Abdul-Ghani, M. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- ORCID
- DeFronzo, Ralph A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-08
- Volume
- 96
- Issue
- 8
- Pages
- 2354-2366
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2131616886
- Cited by
- 247
- References
- 131
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 15 · 2023: 13 · 2022: 7 · 2021: 11 · 2020: 23 · 2019: 12 · 2018: 18 · 2017: 16 · 2016: 19 · 2015: 14 · 2014: 31 · 2013: 28 · 2012: 17
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 2 diabetes prevention, impaired glucose tolerance, beta-cell preservation, insulin resistance, thiazolidinediones, metformin, glucagon-like peptide-1 analogues, acarbose, lifestyle modification, pharmacological interventions, prediabetes
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Prediabetic State, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.